277 related articles for article (PubMed ID: 22272227)
1. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer.
Vathipadiekal V; Saxena D; Mok SC; Hauschka PV; Ozbun L; Birrer MJ
PLoS One; 2012; 7(1):e29079. PubMed ID: 22272227
[TBL] [Abstract][Full Text] [Related]
2. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
3. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary.
May T; Virtanen C; Sharma M; Milea A; Begley H; Rosen B; Murphy KJ; Brown TJ; Shaw PA
Gynecol Oncol; 2010 Apr; 117(1):9-17. PubMed ID: 20117829
[TBL] [Abstract][Full Text] [Related]
4. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways.
Donninger H; Bonome T; Radonovich M; Pise-Masison CA; Brady J; Shih JH; Barrett JC; Birrer MJ
Oncogene; 2004 Oct; 23(49):8065-77. PubMed ID: 15361855
[TBL] [Abstract][Full Text] [Related]
5. [Identification and characterization of stem cells in an ovarian cancer cell line and examination their drug resistance].
Wei Z; Wang Y; Yu X; Zhang S
Zhonghua Fu Chan Ke Za Zhi; 2015 Jun; 50(6):452-7. PubMed ID: 26311554
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
[TBL] [Abstract][Full Text] [Related]
7. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
8. SOX2 expression associates with stem cell state in human ovarian carcinoma.
Bareiss PM; Paczulla A; Wang H; Schairer R; Wiehr S; Kohlhofer U; Rothfuss OC; Fischer A; Perner S; Staebler A; Wallwiener D; Fend F; Fehm T; Pichler B; Kanz L; Quintanilla-Martinez L; Schulze-Osthoff K; Essmann F; Lengerke C
Cancer Res; 2013 Sep; 73(17):5544-55. PubMed ID: 23867475
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
10. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
[TBL] [Abstract][Full Text] [Related]
11. miR-106a represses the Rb tumor suppressor p130 to regulate cellular proliferation and differentiation in high-grade serous ovarian carcinoma.
Liu Z; Gersbach E; Zhang X; Xu X; Dong R; Lee P; Liu J; Kong B; Shao C; Wei JJ
Mol Cancer Res; 2013 Nov; 11(11):1314-25. PubMed ID: 24045973
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
13. Characterization of primary ovarian cancer cells in different culture systems.
Liu T; Cheng W; Lai D; Huang Y; Guo L
Oncol Rep; 2010 May; 23(5):1277-84. PubMed ID: 20372841
[TBL] [Abstract][Full Text] [Related]
14. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma.
Kim YS; Hwan JD; Bae S; Bae DH; Shick WA
BMC Cancer; 2010 Oct; 10():576. PubMed ID: 20969748
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
16. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling.
Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Gokden M; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
Br J Cancer; 2004 May; 90(9):1814-24. PubMed ID: 15208622
[TBL] [Abstract][Full Text] [Related]
17. Differential gene expression analysis of ovarian cancer in a population isolate.
Grazio D; Pichler I; Fuchsberger C; Zolezzi F; Guarnieri P; Heidegger H; Scherer A; Engl B; Messini S; Egarter-Vigl E; Pramstaller PP
Eur J Gynaecol Oncol; 2008; 29(4):357-63. PubMed ID: 18714569
[TBL] [Abstract][Full Text] [Related]
18. Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
Zaid TM; Yeung TL; Thompson MS; Leung CS; Harding T; Co NN; Schmandt RS; Kwan SY; Rodriguez-Aguay C; Lopez-Berestein G; Sood AK; Wong KK; Birrer MJ; Mok SC
Clin Cancer Res; 2013 Feb; 19(4):809-20. PubMed ID: 23344261
[TBL] [Abstract][Full Text] [Related]
19. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
20. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer.
Ghosh S; Albitar L; LeBaron R; Welch WR; Samimi G; Birrer MJ; Berkowitz RS; Mok SC
Gynecol Oncol; 2010 Oct; 119(1):114-20. PubMed ID: 20619446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
